Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed cancer of the urothelium (renal pelvis, ureter, bladder, or urethra)~  * Any of the following types:~    * Transitional cell carcinoma (TCC)~   * Mixed histologies containing a component of TCC~   * Non-TCC of the urothelium (renal pelvis, ureter, bladder, or urethra)~* Progressing regional or metastatic disease~* Measurable disease~* No clinical evidence of CNS metastases~* No evidence of clinically significant (by physical exam or plain film) third-space fluid collections (pleural effusions or ascites)~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 9 g/dL~Hepatic~* AST no greater than 3 times upper limit of normal (ULN)~* Bilirubin no greater than 1.5 times ULN~Renal~* Creatinine clearance at least 45 mL/min~Cardiovascular~* No history of severe cardiovascular disease (i.e., American Heart Association class III or IV heart disease)~* No uncontrolled congestive heart failure~* No ventricular dysrhythmias~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No active unresolved infection~* No other prior malignancy unless curatively treated and disease free for an appropriate (disease-specific) period of time~* Able and willing to receive folic acid and cyanocobalamin supplementation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior systemic biologic response modifier therapy~Chemotherapy~* No prior systemic chemotherapy for metastatic disease~* More than 1 year since prior neoadjuvant or adjuvant chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* At least 4 weeks since prior radiotherapy and recovered~* No prior pelvic radiotherapy~* No concurrent radiotherapy~Surgery~* At least 4 weeks since prior major surgery and recovered~Other~* More than 7 days since prior parenteral antibiotics~* No salicylates for 2 days before, during, and for 2 days after administration of pemetrexed disodium~* No nonsteroidal anti-inflammatory drugs for at least 5 days before, during, and for 2 days after administration of pemetrexed disodium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Pemetrexed Disodium and Gemcitabine (Type: EXPERIMENTAL): Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).